Re: Zenith trial partners
in response to
by
posted on
Jan 29, 2023 03:42PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Pay, I will take a stab a valuation
Pfizer paid 14 Billion usd for Medivation in 2017 to lock up Xandi which was being approved , so I am going to say $1 Billion usd plus royalties is a very very conservative starting point for the potential of Zen 3694 that has a few years before being approved. Dm stated a few times they can try with an earlier approval if the ORR is over 30%
we'll see